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A retroviral vector constructed from the murine leukemia
virus (MLV) can only express transgenes in cells undergoing
mitosis, indicating its suitability as a delivery vehicle for can-
cer gene therapy. However, the transduction efficiency (TE)
of retroviruses embedding endogenous envelope proteins in
human cancer cells was found to be unsatisfactory.
Recently, several research groups have demonstrated the
feasibility of a retroviral vector pseudotyped with a vesicular
stomatitis virus G (VSV-G) protein. In this study, the potential
of VSV-G pseudotyped MLV-based retrovirus was examined
as a delivery vehicle in a variety of human cancer cells
including brain tumor cells in vitro and in vivo. The transduc-
tion efficiency of the 293T/G/GP/LacZ retrovirus in cell cul-
ture was superior in most cancer cells, particularly in brain
tumor cells, compared with that of other retroviruses, such
as PA317- or PG13-derived. The relative growth rate and
phosphatidylserine expression level on the plasma mem-
Keywords: retroviral vector; transduction efficiency; VSV-G; phosphatidylserine; brain tumor
As a gene delivery vehicle in cancer gene therapy, a vec-
tor with preferential selectivity to cycling cells and feasi-
bility of in vivo administration is desirable.1 Retroviral
vectors constructed from the murine leukemia virus
(MLV) can only express transgenes inside target cells
after chromosome integration of the viral genome. It is
essential that the host cells undergo mitosis shortly after
virus infection.2,3 Therefore, quiescent cells, such as nor-
mal tissue adjacent to a targeted tumor, would be refrac-
tory to therapeutic gene expression and consequently
spared from its cytotoxicity, thus indicating the useful-
ness of retroviral vectors.4,5 Replication-incompetent
MLV-based retroviral vectors can be produced by trans-
fecting or infecting a retroviral packaging cell line provid-
ing viral proteins, with a retroviral vector containing a
transgene in place of viral coding genes.6,7 Packaging
cells providing an amphotropic envelope protein, such as
PA317, are most commonly used to produce retroviral
vectors, which infect both murine and human cells.7,8
However, in most human cancer cells the retrovirus gen-
erated from PA317 has suffered from suboptimal trans-
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brane of target cells mainly influenced the transduction
efficiency of VSV-G pseudotyped retrovirus, which sug-
gested that both the relative growth rate and phosphatidyl-
serine expression level were major determinants of TE. Fur-
thermore, 293T/G/GP/LacZ could efficiently transduce
human cancer cells regardless of the presence of chemical
additives, whereas in other retroviruses, cationic chemical
additives such as polybrene or liposomes were essential
during virus infection. Finally, an average of 10% gene
expression was routinely obtained exclusively in the tumor
mass when 293T/G/GP/LacZ concentrated by simple ultra-
centrifugation was directly administrated to pre-established
brain tumors in animal models (U251-N nu/nu mice or C6
Wistar rats). All told, the present study suggests that the
VSV-G pseudotyped retrovirus is a suitable vector for brain
tumor gene therapy. Gene Therapy (2001) 8, 268–273.
duction efficiency, which has limited therapeutic efficacy,
especially in the case of an in vivo situation.1,6,9
A successful retroviral infection initially depends on
the interaction between a viral envelope protein and a
specific cell surface receptor protein on the target cell
membrane.10 The retroviral vector, derived from the
PG13 packaging cell line bearing the gibbon ape leukemia
virus (GALV) envelope protein has shown an improved
transduction efficiency in multiple types of human cancer
cells, compared with that of PA317.11,12 However, the
PG13-derived retrovirus is readily inactivated both by
human serum and by ultracentrifugation.13–15 Further-
more, retroviruses bearing endogenous retrovirus envel-
ope proteins should be complexed with chemical addi-
tives for substantial virus infection.12 For this reason,
polybrene (a polycationic chemical) has been commonly
used9,16–18 and cationic liposomes or other polycations
have been recently used as effective alternatives to polyb-
rene.19–21 Our previous results have demonstrated that
polycationic chemical additives, especially Lipofectamine
(Gibco-BRL, Gaithersburg, MD, USA), greatly enhance
the transduction efficiency of retroviruses derived from
both PA317 and PG13, which is consistent with other
studies.12,17–20 However, these chemical additives were
found to induce cytotoxicity even in vitro, which would
ultimately limit their use in a clinical trial.12,17
Several groups have demonstrated that it is possible to
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stomatitis virus G (VSV-G) protein.14,15,22 The VSV-G
pseudotyped retrovirus appears to have a broad spec-
trum of susceptible cell types, including mammalian and
non-mammalian cells.23,24 In addition, the VSV-G pseudo-
typed retrovirus withstands the shearing force encoun-
tered during ultracentrifugation when generating highly
concentrated virus stocks.25–27
To explore the potential of VSV-G pseudotyped retro-
viral vector as an effective gene delivery vehicle for can-
cer gene therapy, the transduction efficiency of the virus
was investigated in a variety of human cancer cell lines
that originated from different organs, such as human
hepatocellular carcinoma cells (SK-Hep1, Hep3B), human
brain tumor cells (U251-N, U87-MG), human lung cancer
cells (H-460), human breast cancer cells (MCF-7), human
gastric cancer cells (YCC-1) and human cervical cancer
cells (HeLa). For in vitro experiments, the cells were
infected with retroviruses using LacZ as a marker gene
and bearing different types of envelope proteins, such as
PA317 (amphotropic envelope protein)/LacZ, PG13
(gibbon ape leukemia virus envelope protein)/LacZ. Bing
(amphotropic envelope protein)/LacZ, FLYRD18 (cat
RD114 envelope protein)/LacZ and 293T/G/GP (VSV-G
envelope protein)/LacZ at a multiplicity of infection
(MOI) of 10 in the presence of polybrene (4 mg/ml). As
shown in Figure 1a, 293T/G/GP/LacZ and PG13/LacZ
displayed higher transduction efficiencies, especially in
brain tumor cells, compared with the other retroviruses.
The transduction efficiencies obtained from 293T/G/
GP/LacZ in U251-N and U87-MG were scored as 31 – 2%
and 21 – 3%, respectively. However, in several other can-
cer cells, including H-460, MCF-7, YCC-1 and HeLa, all
types of retroviruses at the same MOI showed transduc-
tion efficiencies of less than 5%. U251-N, SK-Hep1, H-460,
MCF-7, Hep3B and YCC-1 were infected with
293T/G/GP/LacZ at various MOIs in order to investi-
gate the effects of the MOIs on the VSV-G pseudotyped
retrovirus transduction efficiency, with the results shown
in Figure 1b. The transduction efficiency up to a MOI of
100 was enhanced by a substantial proportion, parti-
cularly in U251-N, SK-Hep1 and H-460. In contrast, the
other retroviruses containing a Bing-derived retrovirus
did not show an equivalent enhancement of the transduc-
tion efficiency of 293T/G/GP/LacZ by simply infecting
the cells at a higher MOI (data not shown). Therefore,
these results suggest that the VSV-G pseudotyped retro-
virus is superior to other retroviruses in transducing
most human cancer cells. Moreover, the enhanced trans-
duction efficiency in some human cancer cells could be
achieved by simply infecting the cells with higher MOIs
(ie more infectious virus particles).
Since Figure 1 indicates a significantly improved trans-
duction efficiency of the VSV-G pseudotyped retrovirus
in brain tumor cells, the transduction efficiency of
293T/G/GP/LacZ was further examined in a variety of
brain tumor cells. As expected, Figure 2a indicates that
the 293T/G/GP/LacZ retrovirus can efficiently trans-
duce most brain tumor cells. At the highest (MOI of 100),
an average transduction efficiency of 78 – 7% by the
293T/G/GP/LacZ retrovirus was obtained in U251-N,
U343, U87-MG, TE671 and C6 cells. Figure 2b shows that
the transduction efficiency by 293T/G/GP/LacZ in
U251-N cells was 85 – 8% at a MOI of 100, whereas that
by Bing/LacZ was only 8 – 1%. The transduction
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Figure 1 Transduction efficiency of VSV-G pseudotyped retrovirus in a
variety of human cancer cell lines. The values are the averages of at least
three independent experiments, and the error bars indicate the standard
errors of the means, if not specifically described in the figures throughout
this manuscript. (a) Effects on transduction efficiency of retroviruses con-
taining different envelope proteins. All the cell lines were maintained as
described previously12 and retroviral vector pBabe/puro was as is described
elsewhere.12,28 PA317/LacZ, PG13/LacZ, Bing/LacZ and FLYRD18/LacZ
were generated by transfection of pBabe/puro/LacZ to its corresponding
packaging cell lines and established as described previously.12
293T/G/GP/LacZ retrovirus was generated by employing plasmids,
pBCtTA, pMDtetG and pMDgagpol based on the tetracycline-regulated
gene expression system of Gossen and Bujard.29 To determine virus titer
(number of infectious particles per ml of virus supernatant), 293T cells
were infected with serial dilutions of each virus soup containing 4 mg/ml
of polybrene (Sigma, St Louis, MO, USA) to estimate the degree of X-
gal staining or resistance to puromycin (1 mg/ml). Human cancer cells of
2.5 · 104 cells per well in 48-well plates were infected at a MOI of 10
with various retroviruses, and transduction efficiency was determined by
X-gal staining 48 h after infection.12 For X-gal staining in vitro, cells
were fixed in fixing solution (0.2% formaldehyde and 0.2% glutaraldehyde
in dH2O, and then incubated with staining solution (0.4 mg/ml X-gal,
4 mm potassium ferrocyanide, 4 mm potassium ferricyanide, 2 mm MgCl2
in PBS) at 37 ° C for 4 to 16 h. Transduction efficiency (designated as a
transduction unit) was defined as the average number of blue cells per
· 100 field multiplied by magnification factors, plate size and dilution of
the infectious stock. (b) Effects of 293T/G/GP/LacZ at different MOIs on
transduction efficiency. Differences on the transduction efficiency of
293T/G/GP/LacZ at various MOIs was investigated by infecting the cells
at indicated MOIs of 293T/G/GP/LacZ virus and measuring the degree
of X-gal staining.
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Figure 2 Enhanced transduction efficiencies in a variety of brain tumor
cells by VSV-G pseudotyped retrovirus. (a) Transduction efficiency in
brain tumor cells by 293T/G/GP/LacZ at different MOIs. Transduction
efficiency was determined after infecting the cells with 293T/G/GP/LacZ
at various MOIs. (b) Comparison of transduction efficiency by
293T/G/GP/LacZ and Bing/LacZ. Transduction efficiency of
293T/G/GP/LacZ or Bing/LacZ virus at MOIs of 10 or 100 was investi-
gated by infecting U251-N cells.
efficiency by 293T/G/GP/LacZ in U251-N and U87-MG
were even superior to that obtained by a recombinant
adenovirus (data not shown). When compared with
Figure 1, it suggests that the VSV-G pseudotyped retro-
virus can transduce brain tumor cells most efficiently
over any other type of retrovirus or a recombinant aden-
ovirus. Yet, the VSV-G pseudotyped retrovirus still could
not enhance the transduction efficiency in some cancer
cell lines, including YCC-1, Hep3B, and HeLa cells, which
have previously shown an extremely low transduction
efficiency with other retroviruses.12 Many research
groups including this one have demonstrated that the
efficient gene transfer by MLV-based retrovirus initially
relies on the subsequent mitosis of host cells shortly after
virus infection.2,3,12 Based on this, the relative growth rate
of these cells was determined by counting the cells30
(Figure 3a) or by performing a modified MTT assay (data
not shown; Promega, Madison, WI, USA). Figure 3a
shows that Daoy, Hep3B, YCC-1, HeLa and SH-SY5Y
(panels C and D) have slow growth rate (below
0.52 – 0.02% in relative growth rate), compared with the
other cells including MCF-7 and SK-Hep1 in panel A, H-
460, C6, U251-N, U87-MG, TE671 and U343 in panel B
(over 0.65 – 0.01%). Despite the fast growth rate in the
case of H-460, SK-Hep1 and MCF-7, these cancer cells
suffered from a low transduction efficiency (below 6.4%
– 0.4% at a MOI of 10). However, all the cells with a high
Figure 3 Effects of the relative growth rates and phosphatidylserine levels
on the transduction efficiency of VSV-G pseudotyped retrovirus. (a) Rela-
tive growth rate, phosphatidylserine level and transduction efficiency of
293T/G/GP/LacZ in a variety of cancer cells. To estimate the level of phos-
phatidylserine in a variety of cancer cells, cells in 25T flasks were dis-
sociated, resuspended in binding buffer and then incubated with 5 ml of
FITC-labeled annexin V (Clontech, Palo Alto, CA, USA) as supplied by
the manufacturer at room temperature for 10 min in the dark. FACS
analysis was performed to the manufacturer’s instructions and the relative
phosphatidylserine level was determined by the following equation. Rela-
tive phosphatidylserine level = the level of FITC-positive cells in the
sample/the level of FITC-positive Daoy cells. To calculate the relative cell
growth rate, 1 · 103 cells were inoculated into 48-well culture plates, har-
vested and counted at 48 h intervals. The relative cell growth rate was
determined by the following equation. Relative cell growth rate = doubling
time of C6 cells/doubling time of the cells under test. Transduction
efficiency was determined by infecting the cells at a MOI of 10 in the
presence of polybrene. (b) Correlation of transduction efficiency with cell
growth rate and phosphatidylserine level. Transduction efficiencies of each
cell line by VSV-G pseudotyped retrovirus at a MOI of 10 are indicated
in parenthesis.
transduction efficiency (C6, TE671, U87-MG, U343, U251-
N in panel B) had a fast growth rate. This suggests that
the mitosis of target cell shortly after virus infection is
necessary for efficient transgene expression by a VSV-G
pseudotyped retrovirus, but on its own is not a suf-
ficient condition.
The VSV-G protein primarily recognizes the phospholi-
pid membrane ubiquitously present, such as phosphatid-
ylserine, instead of a specific cell surface protein.23,31,32 To
investigate the correlation between the presence of phos-
phatidylserine (a major binding target on cell membrane
for VSV-G protein) with the transduction efficiency by
the VSV-G pseudotyped retrovirus in cancer cells, the
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measured using FITC-labeled annexin V. Annexin V, a
vascular protein with strong anticoagulant properties,
binds preferentially to a negatively charged phospholi-
pid, such as phosphatidylserine.33–35 It was found that the
phosphatidylserine level in a variety of cancer cells was
rather diverse (Figure 3a). C6, U251-N, TE671, U87-MG,
U343, YCC-1, H-460 and Daoy (panels B and D) embed-
ded a substantial level of phosphatidylserine on the cell
surface (over 0.54 – 0.03%), whereas HeLa, SK-Hep1,
Hep3B, MCF-7 and SH-SY5Y (panels A and C) expressed
a significantly lower level (below 0.32 – 0.05%). Addition-
ally, Figure 3 indicates that brain tumor cell lines with a
significantly high transduction efficiency (78 – 7% at a
MOI of 100), except SH-SY5Y and Daoy (17 – 3%,
27 – 4%, respectively, at the same MOI), are located in
panel B. These cell lines experienced a significantly faster
growth rate (from 1.00 – 0.10% to 0.65 – 0.50%) and
higher phosphatidylserine expression (from near
0.76 – 0.04 to 0.54 – 0.03%). Thus, this supports the idea
that both the cell growth rate and phosphatidylserine
expression level are major determinants of the VSV-G
pseudotyped MLV-based retrovirus transduction
efficiency. All told, the results suggest that the low phos-
phatidylserine expression level or poor human cancer cell
growth rate may limit efficient gene transfer by the VSV-
G pseudotyped retrovirus. The only exception was H-460
(less than 3.0 – 0.5% in transduction efficiency at a MOI
of 10), which expressed the high phosphatidylserine level
(0.75 – 0.10 in relative phosphatidylserine level) and a
fast growth rate (0.98 – 0.07 in relative growth rate).
Unfortunately, the reason for the poor H-460 transduc-
tion efficiency cannot be explained in our studies. How-
ever, the poor transduction efficiency of H-460 could be
influenced by the lack of undefined host cellular factor(s)
or other unknown reasons, which influence the ultimate
transduction efficiency by the MLV-derived retro-
virus.6,7,9
In previous studies, other research groups including
this one have consistently reported the improved trans-
duction efficiency of various retroviral vectors complexed
with chemical additives, including cationic lipo-
somes.12,19–21 Based on this, the effects of chemical addi-
tives on the transduction efficiency in human brain tumor
cells by 293T/G/GP/LacZ were studied in the presence
of various polycationic reagents, including polybrene,
protamine sulfate and cationic liposomes (Figure 4). Sur-
prisingly, 293T/G/GP/LacZ efficiently transduced the
brain tumor cells in the absence of cationic chemical addi-
tives (Figure 4a), whereas in PG13/LacZ or other retrovi-
ral vectors, chemical additives were essential. To deter-
mine whether the ratio of retrovirus and liposome
concentration can influence the transduction efficiency, a
fixed number of 293T/G/GP/LacZ were incubated with
various concentrations of Lipofectamine and the resulting
transduction efficiency was determined (Figure 4b). The
figure shows that transduction efficiency did not increase
significantly in 293T/G/GP/LacZ complexed with Lipo-
fectamine, with only a 1.7 – 0.5-fold increase (U87-MG)
and 1.4 – 0.1 (U251-N) at 0.1· of relative Lipofectamine
ratio. Furthermore, a consistent decrease in the transduc-
tion efficiency in most concentrations of Lipofectamine
was observed in all the cells tested. A similar degree of
reduced transduction efficiency was found under ident-
ical conditions when using other kinds of liposome, such
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Figure 4 Effects of cationic chemical additives on the transduction
efficiency of VSV-G pseudotyped retrovirus. (a) Effects of chemical addi-
tives on the transduction efficiency of 293T/G/GP/LacZ in brain tumor
cells. 293T/G/GP/LacZ at a MOI of 5 was pre-incubated with no agent,
polybrene, protamine sulfate, DOTAP, DC-Chol/DOPE or Lipofectamine.
For liposome treatment, equal volumes of virus soup were mixed with
liposome solution at the designated concentration, 200 ml of the mixture
was added to the cells for 4 h, and the cells were then refed with fresh
media. Protamine sulfate (Sigma) was diluted to 10 mg/ml and treated in
the same manner as polybrene, as described previously.12 Transduction
efficiency was determined by X-gal staining 2 days after infection, as
described in Figure 1. (b) Relative transduction efficiency of
293T/G/GP/LacZ complexed with Lipofectamine. Values indicate the
ratios of the relative transduction efficiency of Lipofectamine treated/the
transduction efficiency in the absence of chemical additives.
as DC-Chol/DOPE or DOTAP (data not shown). Con-
versely, the concentration initially used (1 · ) was optimal
for PG13/LacZ and a relative transduction efficiency by
PG13/LacZ increased up to 126 – 8-fold (U87-MG) and
124 – 16-fold (U251-N), when compared with that in the
absence of chemical additives (data not shown). Consist-
ently, a similar pattern in the transduction efficiency of
PG13/LacZ was observed with other types of retroviral
vectors (data not shown). Burns et al25 demonstrated that
a complete omission of polycationic additives during
VSV-G pseudotyped retrovirus infection resulted in a
100-fold reduction in the number of normal cells, such as
the MDCK cell (canine kidney cell). However, Costello et
al27 recently reported that the VSV-G pseudotyped HIV-
1 vector using polybrene only enhanced the transduction
efficiency of human T lymphocytes by approximately
two times. Furthermore, in all the human cancer cell lines
VSV-G pseudotyped retrovirus for brain tumor gene therapy
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tested in this study, subsequently enhanced gene transfer
was not detected when using different kinds of cationic
chemicals, including polybrene and different cationic
liposomes. Overall, these observations suggest that
unlike other retroviruses, the VSV-G pseudotyped retro-
virus does not require chemical additives for efficient
transduction in brain tumor cells.
The major advantage of the VSV-G pseudotyped retro-
virus is its resistance to ultracentrifugation and human
serum.25,26,36 It was also observed that 293T/G/GP/LacZ
could be readily concentrated by simple centrifugation
with little reduction in viability, which concurs with
other reports. In this study, approximately 1 to 2 · 107
infectious 293T/G/GP/LacZ particles/ml could be easily
recovered from 293T/G/GP/LacZ producer cells. Fur-
thermore, the 293T/G/GP/LacZ virus could be concen-
trated up to 500-fold, reaching up to 1 · 1010 infectious
particles/ml with less than 10 – 5% loss of initial infec-
tivity (data not shown). When 293T/G/GP/LacZ was
incubated with human serum at 37° C for 3 h, the
293T/G/GP/LacZ retained about 40 – 10% of its initial
virus infectivity, whereas the PA317/LacZ virus retained
only 5 – 1% (data not shown). These characteristics may
allow the VSV-G retroviral vector to become a suitable
delivery vehicle in vivo. In investigating whether the
293T/G/ GP/LacZ virus can transduce human brain
tumor cells efficiently in vivo, a U251-N pre-existing
abdominal tumor in nu/nu mice or a C6 brain tumor ster-
eotaxically implanted into a Wistar rat were intratumor-
ally injected with 293T/G/GP/LacZ virus. Figure 5
shows that the transduction efficiency of
293T/G/GP/LacZ in vivo reached an average of around
10% in both cases, indicating that efficient transduction
by the VSV-G pseudotyped retrovirus can be readily ach-
ieved by a direct intratumoral injection. Recently, Gali-
peau et al37 reported that the VSV-G pseudotyped retro-
virus, containing thymidine kinase as a therapeutic gene,
led to significant GCV sensitization in a C6 glioma tumor
model. Extremely few human malignant gliomas are cur-
able with the conventional modality, including surgery,
radiation therapy, and chemotherapy.38,39 In this regard,
gene transfer strategy has been intensively investigated
recently as a new concept for alternative glioma tumor
treatment.40,41 This investigation, taken together with Gal-
ipeau’s study, demonstrates the feasibility of the VSV-G
pseudotyped MLV-based retrovirus for cancer gene
therapy, especially for brain tumors in vivo.
In summary, the transduction efficiency of VSV-G
pseudotyped retrovirus in a variety of human cancer cells
and the effects of chemical additives on its transduction
efficiency in vitro and in vivo was examined. It was dem-
onstrated that the VSV-G pseudotyped retrovirus could
efficiently transduce a variety of cancer cells, especially
brain tumor cells in vivo as well as in vitro, in the absence
of chemical additives. These results suggest the possi-
bility of the VSV-G pseudotyped retrovirus vector as a
suitable vector for direct in vivo gene transfer in brain
tumors.
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